In summary, our findings uncover a critical role for BRAF/TBX3/CXCLs signaling in the regulation of anti-tumor immunity and suggest the use of combination CXCR2 inhibitor with MAPKi therapy in patients with advanced PTC. This evidence concerns the gene CXCR2 and neoplasm.